We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pharmacokinetics of the Fixed Dose Combination of Tiotropium Plus BI 54903 Versus the Combination of the Monoproducts of Tiotropium and BI 54903 in Healthy Volunteers

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01309139
First Posted: March 4, 2011
Last Update Posted: November 1, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Boehringer Ingelheim
  Purpose

The primary objective is to compare the systemic exposure to tiotropium and CD 1857 after treatment with the fixed dose combination (fixed dose combination (FDC), Treatment A) of tiotropium plus BI 54903 (ethanolic solution for inhalation (EIS), Respimat (RMT) B) with the systemic exposure following inhalation of the free combination (Treatment B) of tiotropium (aqueous solution for inhalation (AIS), RMT A) plus BI 54903 (EIS, RMT B), when administered once-daily over 21 days via Respimat(R) (RMT).

The secondary objectives are:

to compare the systemic exposure to tiotropium and CD 1857 after single dose administration of FDC and of the free combination of tiotropium/BI 54903 to compare the systemic exposure to BI 54903 after a single dose and at steady state after multiple doses of the FDC and of the free combination of tiotropium/BI 54903 to compare the safety and tolerability of tiotropium and BI 54903 when administered as FDC and as free dose combination, respectively


Condition Intervention Phase
Healthy Drug: Tiotropium Drug: BI 54903 Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label, Randomised, Two-way Crossover Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of Tiotropium Plus BI 54903 Via Respimat® B Versus the Combination of the Monoproducts of Tiotropium Via Respimat® A and BI 54903 Via Respimat® B in Healthy Volunteers

Resource links provided by NLM:


Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • Area under the concentration time curve of CD 1857 in plasma over a uniform dosing interval τ (AUCτ,ss) [ Time Frame: on several time points until day 22 ]
  • Maximum concentration of CD 1857 in plasma at steady state (Cmax,ss) [ Time Frame: on several time points until day 22 ]
  • AUCτ,ss for Tiotropium [ Time Frame: on several time points until day 22 ]
  • Cmax,ss for Tiotropium [ Time Frame: on several time points until day 22 ]

Secondary Outcome Measures:
  • AUCτ,ss for BI 54903 [ Time Frame: on several time points until day 22 ]
  • Cmax,ss for BI 54903 [ Time Frame: on several time points until day 22 ]
  • Ae0-24 (Amount of analyte that is eliminated in urine) for tiotropium [ Time Frame: on Day 1 and 21 ]
  • Change in physical examination [ Time Frame: 9 weeks ]
  • Change in vital signs [ Time Frame: 9 weeks ]
  • Change in 12-lead electrocardiogram [ Time Frame: 9 weeks ]
  • Change in clinical laboratory tests [ Time Frame: 9 weeks ]
  • Occurrence of Adverse Events [ Time Frame: 9 weeks ]
  • Assessment of tolerability by the investigator [ Time Frame: 9 weeks ]

Enrollment: 36
Study Start Date: March 2011
Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment A: Tiotropium medium dose
Oral inhalation daily for 21 days
Drug: Tiotropium
Medium dose of oral inhalation
Experimental: Treatment A: BI 54903 high dose
Oral inhalation daily for 21 days
Drug: BI 54903
Medium dose of oral inhalation
Experimental: Treatment B: Tiotropium medium dose
Oral inhalation daily for 21 days
Drug: Tiotropium
Medium dose of oral inhalation
Experimental: Treatment C: BI 54903 high dose
Oral inhalation daily for 21 days
Drug: BI 54903
Medium dose of oral inhalation

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   21 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion criteria:

  1. Healthy males and females according to the following criteria: Based upon a complete medical history, including the physical examination, vital signs (blood pressure (BP), pulse rate (PR)), 12-lead electrocardiogram (ECG), clinical laboratory tests.
  2. Age 21 to 50 years.

Exclusion criteria:

  1. Any finding of the medical examination (including BP, PR and ECG) deviating from normal and of clinical relevance
  2. Any evidence of a clinically relevant concomitant disease
  3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  4. History or evidence of relevant psychiatric disorders or neurological disorders
  5. History or evidence of relevant autonomic dysfunction (orthostatic hypotension, fainting spells or blackouts)
  6. Chronic or relevant acute infections
  7. History of relevant allergy/hypersensitivity (including allergy to drug or its excipients)
  8. Intake of any prescription drugs or over-the-counter (over the counter (OTC)) medication (vitamins, herbal supplements, dietary supplements) with a long half-life (> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
  9. Participation in another trial with an investigational drug within two months prior to administration or during the trial
  10. Smoker (more than 10 cigarettes daily)
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01309139


Locations
Germany
1298.2.1 Boehringer Ingelheim Investigational Site
Ingelheim, Germany
Sponsors and Collaborators
Boehringer Ingelheim
Investigators
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT01309139     History of Changes
Other Study ID Numbers: 1298.2
2010-023780-18 ( EudraCT Number: EudraCT )
First Submitted: March 1, 2011
First Posted: March 4, 2011
Last Update Posted: November 1, 2013
Last Verified: October 2013

Additional relevant MeSH terms:
Tiotropium Bromide
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Parasympatholytics
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action